Anelixis Therapeutics was formed in 2013 as a for-profit subsidiary of ALS Therapy Development Institute (ALS TDI,, a nonprofit biotechnology organization dedicated to developing effective treatments for ALS. Every member of the Anelixis Therapeutics team is committed to advancing treatments that will have a meaningful impact on the lives of patients by helping them battle back their disease progression.

Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts with a portfolio focused on immune modulatory drugs for neurodegenerative diseases with a focus on amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease (AD).

Anelixis Therapeutics is developing monoclonal antibodies that block a specific immune system target expressed on lymphocytes (CD40LG) known to drive neurodegeneration. By way of exclusive licensing arrangements with ALS TDI, Anelixis has the right to the development of methods to treat ALS by administering an antibody that blocks the interaction of CD40 and CD40LG, among other targets. Patents held under license by Anelixis have been issued or are pending in the US, Hong Kong, Japan and Europe. For a preview of current patent status, click here.

Anelixis Therapeutics’ lead candidate, developed on the basis of these patents is AT-1501. AT-1501 has showed success in reducing the activation of specific aspects of the immune system, which in turn slows the progression of disease. The process by which AT-1501 accomplishes this exciting outcome is explained further here.

Anelixis Therapeutics has assembled an expert clinical advisory team and consulting team. The company has developed a cell line and manufacturing process to develop AT-1501. The team has completed IND-enabling toxicology studies in non-human primates and intends to file an IND for first in human studies in early 2018.

To support the further development of AT-1501 toward clinical trial, Anelixis Therapeutics has been awarded philanthropic grant support from several of the most well-known and respected funders of ALS research, including the ALS Association, the ALS Finding a Cure Foundation and ALS ONE.

For more information about Anelixis Therapeutics investment opportunities, contact us.